Physician profile
Adam Bloom
NPI 1740375047
$2,587.24
in general payments reported to CMS, 2019-2025
24 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $166 · 2021: $442 · 2022: $339 · 2023: $418 · 2024: $602 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,400 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,400.24 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $452.55 | 2022-2025 | Clareon, Simbrinza, Tryptyr |
| Abbvie INC. | $331.43 | 2022-2025 | Durysta, Alphagan P, Vuity |
| Allergan, INC. | $303.45 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $213.34 | 2019-2025 | Cequa |
| Kala Pharmaceuticals, INC. | $160.12 | 2019-2021 | |
| Biotissue Holdings INC. | $139.96 | 2023-2024 | |
| Oyster Point Pharma, INC. | $102.52 | 2022-2023 | Tyrvaya |
| Ocular Therapeutix, INC. | $99.27 | 2019-2024 | Dextenza |
| Harrow Eye, LLC | $91.02 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $88.59 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $85.69 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $84.36 | 2022-2025 | Vyzulta, Prolensa, Lotemax Sm |
| Genentech USA, INC. | $81.79 | 2024-2025 | Vabysmo |
| Eyevance Pharmaceuticals LLC | $70.23 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $62.76 | 2020-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $42.04 | 2022-2023 | Tearcare System |
| Amgen INC. | $35.45 | 2024-2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $32.92 | 2019-2021 | |
| Rxsight INC | $22.81 | 2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Horizon Therapeutics Plc | $22.29 | 2019 | |
| Astellas Pharma US INC | $19.17 | 2024 | Izervay |
| Dompe US, INC. | $17.68 | 2019 | |
| Mallinckrodt Hospital Products INC. | $14.07 | 2022 | |
| Rayner Intraocular Lenses Limited | $13.73 | 2025 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.